Seizert Capital Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Seizert Capital Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,400	Closed	-$280K	–	167
2024 Q2	$280K	Sell	4,400 -605	-12%	-$39.3K	0.01%	145
2024 Q1	$346K	Hold	5,005	–	–	0.02%	140
2023 Q4	$276K	Sell	5,005 -1,395	-22%	-$76.8K	0.01%	159
2023 Q3	$372K	Buy	6,400 +2,003	+46%	+$116K	0.02%	142
2023 Q2	$237K	Buy	+4,397	New	+$195K	0.01%	168
2020 Q3	–	Sell	-29,902	Closed	-$967K	–	191
2020 Q2	$967K	Sell	29,902 -4,969	-14%	-$178K	0.07%	115
2020 Q1	$1.42M	Sell	34,871 -3,060	-8%	-$163K	0.1%	85
2019 Q4	$2.34M	Sell	37,931 -1,114	-3%	-$73.8K	0.12%	84
2019 Q3	$2.85M	Buy	39,045 +9,648	+33%	+$722K	0.14%	81
2019 Q2	$2.42M	Buy	+29,397	New	+$2.09M	0.12%	87

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Seizert Capital Partners's ANIP Position: Q3 2024 in Review

Seizert Capital Partners sold out of ANI Pharmaceuticals (ANIP) in Q3 2024, closing a stake of 4,400 shares — an estimated $280K sold.

Seizert Capital Partners first reported a position in ANIP in Q2 2019 and held it in 10 quarters. The position peaked at $2.85M in Q3 2019. 208 funds tracked by Wall St. Rank hold ANIP as of Q3 2024.

Seizert Capital Partners reported no remaining ANI Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Seizert Capital Partners sold 4,400 ANI Pharmaceuticals shares in Q3 2024, an estimated $280K.
Seizert Capital Partners first reported a position in ANI Pharmaceuticals in Q2 2019 and held it in 10 quarters.
Seizert Capital Partners's ANI Pharmaceuticals position peaked at $2.85M in Q3 2019.
208 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2024.

Based on Seizert Capital Partners's 13F filing for Q3 2024, filed 6 Nov 2024.